Table_14_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls by Congjun Wang (1267932)

“…In addition, protein expressions of COL1A1, COL5A1, E-cadherin, N-cadherin, Snail, and Vimentin were identified via Western blot (WB) assay. …”

Table_5_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls by Congjun Wang (1267932)

“…In addition, protein expressions of COL1A1, COL5A1, E-cadherin, N-cadherin, Snail, and Vimentin were identified via Western blot (WB) assay. …”

Table14_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls by Congjun Wang (1267932)

“…In addition, protein expressions of COL1A1, COL5A1, E-cadherin, N-cadherin, Snail, and Vimentin were identified via Western blot (WB) assay. …”

Table_8_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls by Congjun Wang (1267932)

“…In addition, protein expressions of COL1A1, COL5A1, E-cadherin, N-cadherin, Snail, and Vimentin were identified via Western blot (WB) assay. …”

Table11_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls by Congjun Wang (1267932)

“…In addition, protein expressions of COL1A1, COL5A1, E-cadherin, N-cadherin, Snail, and Vimentin were identified via Western blot (WB) assay. …”

Table2_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls by Congjun Wang (1267932)

“…In addition, protein expressions of COL1A1, COL5A1, E-cadherin, N-cadherin, Snail, and Vimentin were identified via Western blot (WB) assay. …”

S4 Fig - by R. J. S. D. Heine (17889199)

“…</p><p>Methods</p><p>The model was used to calculate cumulative yearly prices, cumulative prices per indication, and non-cumulative indication-based prices using inputs such as research and development (R&D) costs, manufacturing costs, eligible patient population, and a profit margin. A deterministic stepwise analysis and scenario analysis were conducted to examine how sensitive the estimated price is to the different input assumptions.…”

S1 Fig - by R. J. S. D. Heine (17889199)

“…</p><p>Methods</p><p>The model was used to calculate cumulative yearly prices, cumulative prices per indication, and non-cumulative indication-based prices using inputs such as research and development (R&D) costs, manufacturing costs, eligible patient population, and a profit margin. A deterministic stepwise analysis and scenario analysis were conducted to examine how sensitive the estimated price is to the different input assumptions.…”

S5 Fig - by R. J. S. D. Heine (17889199)

“…</p><p>Methods</p><p>The model was used to calculate cumulative yearly prices, cumulative prices per indication, and non-cumulative indication-based prices using inputs such as research and development (R&D) costs, manufacturing costs, eligible patient population, and a profit margin. A deterministic stepwise analysis and scenario analysis were conducted to examine how sensitive the estimated price is to the different input assumptions.…”

S3 Fig - by R. J. S. D. Heine (17889199)

“…</p><p>Methods</p><p>The model was used to calculate cumulative yearly prices, cumulative prices per indication, and non-cumulative indication-based prices using inputs such as research and development (R&D) costs, manufacturing costs, eligible patient population, and a profit margin. A deterministic stepwise analysis and scenario analysis were conducted to examine how sensitive the estimated price is to the different input assumptions.…”

S6 Fig - by R. J. S. D. Heine (17889199)

“…</p><p>Methods</p><p>The model was used to calculate cumulative yearly prices, cumulative prices per indication, and non-cumulative indication-based prices using inputs such as research and development (R&D) costs, manufacturing costs, eligible patient population, and a profit margin. A deterministic stepwise analysis and scenario analysis were conducted to examine how sensitive the estimated price is to the different input assumptions.…”

Input parameters for the base-case analysis. by R. J. S. D. Heine (17889199)

“…</p><p>Methods</p><p>The model was used to calculate cumulative yearly prices, cumulative prices per indication, and non-cumulative indication-based prices using inputs such as research and development (R&D) costs, manufacturing costs, eligible patient population, and a profit margin. A deterministic stepwise analysis and scenario analysis were conducted to examine how sensitive the estimated price is to the different input assumptions.…”

S2 Fig - by R. J. S. D. Heine (17889199)

“…</p><p>Methods</p><p>The model was used to calculate cumulative yearly prices, cumulative prices per indication, and non-cumulative indication-based prices using inputs such as research and development (R&D) costs, manufacturing costs, eligible patient population, and a profit margin. A deterministic stepwise analysis and scenario analysis were conducted to examine how sensitive the estimated price is to the different input assumptions.…”

S1 Data - by R. J. S. D. Heine (17889199)

“…</p><p>Methods</p><p>The model was used to calculate cumulative yearly prices, cumulative prices per indication, and non-cumulative indication-based prices using inputs such as research and development (R&D) costs, manufacturing costs, eligible patient population, and a profit margin. A deterministic stepwise analysis and scenario analysis were conducted to examine how sensitive the estimated price is to the different input assumptions.…”

Quisinostat-mediated HDAC inhibition results in a dissociation of the driving complex in synovial sarcoma. by Aimée N. Laporte (3617987)

Subjects:

Analysis of ERSP response for the PZ channel by comparing each condition in a pairwise manner. by Howe Yuan Zhu (17283139)

Hepatosomatic index % (a); Spleen somatic index % (b) in tilapia in different experimental groups. by Sinthia Kabir Mumu (17705902)

Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists by Dilip K. Tosh (1668115)

“…While screening off-target effects of rigid (<i>N</i>)-methanocarba-adenosine 5′-methylamides as A₃ adenosine receptor (AR) agonists, we discovered μM binding hits at the δ-opioid receptor (DOR) and translocator protein (TSPO). …”

Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists by Dilip K. Tosh (1668115)

“…While screening off-target effects of rigid (<i>N</i>)-methanocarba-adenosine 5′-methylamides as A₃ adenosine receptor (AR) agonists, we discovered μM binding hits at the δ-opioid receptor (DOR) and translocator protein (TSPO). …”

Differences of alpha(a) and NMDS(b) analysis of intestinal flora in mouse of three groups. by Wenxin Ye (14392899)